Lunit 与 Summit 达成研究协议，评估 Lunit SCOPE IO 病理平台用于 ivonescimab 肿瘤微环境分析
Lunit and Summit to evaluate pathology platform for tumour analysis
Lunit 与 Summit Therapeutics 达成研究协议，将用 AI 病理平台 Lunit SCOPE IO 分析接受 ivonescimab 评估的免疫肿瘤项目中的肿瘤微环境。平台基于 H&E 染色全切片图像识别生物标志物、进行患者分层并研究 ivonescimab 的生物学反应，无需额外实验室染色或检测。双方合作不涉及临床结局数据的披露。
Lunit will examine haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics.
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.
Under the partnership, the platform will be applied to haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies plan to utilise the tool to identify biomarkers, stratify patients, and investigate biological responses to ivonescimab.
Lunit SCOPE IO evaluates routine tissue slides to analyse spatial interactions, stromal organisation, and immune cell infiltration without requiring extra laboratory stains or assays. The partnership does not include the disclosure of clinical outcome data.
Summit chief research and development strategy officer Allen Yang said: “Understanding the tumour microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations.
“We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab.”
Also designated as SMT112 and AK112, ivonescimab is an investigational bispecific antibody.
Invented by Akeso, the therapy received marketing authorisation in China in May 2024 but lacks regulatory approval in Summit territories such as Europe and the US.
Across Summit’s licenced regions, which comprise Africa, Europe, Japan, the Middle East, North America, and South America, the therapy remains investigational.
More than 5,000 clinical trial participants worldwide and above 100,000 commercial patients in China have received ivonescimab.
A total of 17 Phase III studies are announced, active, or concluded, including five global trials sponsored by Summit, two run by cooperative groups, and ten conducted by Akeso.
Earlier this month, AstraZeneca and Daiichi Sankyo partnered with Summit to explore the potential of their co-developed antibody-drug conjugate, Datroway (datopotamab deruxtecan), alongside ivonescimab.
来源：Pharmaceutical Technology · pharmaceutical-technology.com